These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37457724)

  • 1. Corrigendum: Patients' IgLON5 autoantibodies interfere with IgLON5-protein interactions.
    Landa J; Serafim AB; Gaig C; Saiz A; Koneczny I; Hoftberger R; Santamaria J; Dalmau J; Graus F; Sabater L
    Front Immunol; 2023; 14():1233632. PubMed ID: 37457724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients' IgLON5 autoantibodies interfere with IgLON5-protein interactions.
    Landa J; Serafim AB; Gaig C; Saiz A; Koneczny I; Hoftberger R; Santamaria J; Dalmau J; Graus F; Sabater L
    Front Immunol; 2023; 14():1151574. PubMed ID: 37033996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome.
    Sabater L; Planagumà J; Dalmau J; Graus F
    J Neuroinflammation; 2016 Sep; 13(1):226. PubMed ID: 27586161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IgLON5 antibodies cause progressive behavioral and neuropathological changes in mice.
    Ni Y; Feng Y; Shen D; Chen M; Zhu X; Zhou Q; Gao Y; Liu J; Zhang Q; Shen Y; Peng L; Zeng Z; Yin D; Hu J; Chen S
    J Neuroinflammation; 2022 Jun; 19(1):140. PubMed ID: 35690819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegeneration Induced by Anti-IgLON5 Antibodies Studied in Induced Pluripotent Stem Cell-Derived Human Neurons.
    Ryding M; Gamre M; Nissen MS; Nilsson AC; Okarmus J; Poulsen AAE; Meyer M; Blaabjerg M
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease.
    Koneczny I; Macher S; Hutterer M; Seifert-Held T; Berger-Sieczkowski E; Blaabjerg M; Breu M; Dreyhaupt J; Dutra LA; Erdler M; Fae I; Fischer G; Frommlet F; Heidbreder A; Högl B; Klose V; Klotz S; Liendl H; Nissen MS; Rahimi J; Reinecke R; Ricken G; Stefani A; Süße M; Teive HAG; Weis S; Berger T; Sabater L; Gaig C; Lewerenz J; Höftberger R
    Front Immunol; 2024; 15():1376456. PubMed ID: 38827736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IgLON5 disease: a novel topic beyond neuroimmunology.
    Zhang YH; Ni Y; Gao YN; Shen DD; He L; Yin D; Meng HY; Zhou QM; Hu J; Chen S
    Neural Regen Res; 2023 May; 18(5):1017-1022. PubMed ID: 36254983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration.
    Landa J; Gaig C; Plagumà J; Saiz A; Antonell A; Sanchez-Valle R; Dalmau J; Graus F; Sabater L
    Ann Neurol; 2020 Nov; 88(5):1023-1027. PubMed ID: 32740999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-LGI1 Encephalitis With Co-occurring IgLON5 Antibodies: Clinical Features and Human Leukocyte Antigen Haplotypes.
    Schiff P; Muñiz-Castrillo S; Do LD; Fantini ML; Chanson E; Rogemond V; Honnorat J; Poncet-Megemont L
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37217310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-IGLON5 disease: A new case without neuropathologic evidence of brainstem tauopathy.
    Erro ME; Sabater L; Martínez L; Herrera M; Ostolaza A; García de Gurtubay I; Tuñón T; Graus F; Gelpi E
    Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31826985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the clinical spectrum of anti-IgLON5 disease: A multicenter retrospective study.
    Ni Y; Shen D; Zhang Y; Song Y; Gao Y; Zhou Q; He L; Yin D; Wang Y; Song F; Chen M; Lian Y; Chen Y; Zhao X; Zhang X; Chen X; Wang Y; Zhang L; Mo N; Lv D; Liu J; Mao Z; Peng L; Chen S
    Eur J Neurol; 2022 Jan; 29(1):267-276. PubMed ID: 34543501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgLON5 autoimmunity tested positive in patients with isolated chronic insomnia disease.
    Aghelan Z; Karima S; Ghadami MR; Khazaie H; Bahrehmand F; Vaisi-Raygani A; Abtahi SH; Khodarahmi R
    Clin Exp Immunol; 2022 Apr; 207(2):237-240. PubMed ID: 35020856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purified Serum IgG from a Patient with Anti-IgLON5 Antibody Cause Long-Term Movement Disorders with Impaired Dopaminergic Pathways in Mice.
    Gao Y; Li H; Luo H; Ni Y; Feng Y; He L; Zhou Q; Hu J; Chen S
    Biomedicines; 2023 Sep; 11(9):. PubMed ID: 37760924
    [No Abstract]   [Full Text] [Related]  

  • 14. Case Report: Neuropsychological Findings in IgLON5 Antibody Disorder.
    El Shazly J; Juenemann M; Gerriets T; Tschernatsch M
    Front Neurol; 2021; 12():632497. PubMed ID: 33633675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis.
    Hansen N; Hirschel S; Stöcker W; Manig A; Falk HS; Ernst M; Vukovich R; Zerr I; Wiltfang J; Bartels C
    Front Psychiatry; 2020; 11():589466. PubMed ID: 33061928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.
    Gaig C; Ercilla G; Daura X; Ezquerra M; Fernández-Santiago R; Palou E; Sabater L; Höftberger R; Heidbreder A; Högl B; Iranzo A; Santamaria J; Dalmau J; Graus F
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31454761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of inflammatory markers and tau deposits in an autopsy series of nine patients with anti-IgLON5 disease.
    Berger-Sieczkowski E; Endmayr V; Haider C; Ricken G; Jauk P; Macher S; Pirker W; Högl B; Heidbreder A; Schnider P; Bradley-Zechmeister E; Mariotto S; Koneczny I; Reinecke R; Kasprian G; Weber C; Bergmann M; Milenkovic I; Berger T; Gaig C; Sabater L; Graus F; Gelpi E; Höftberger R
    Acta Neuropathol; 2023 Oct; 146(4):631-645. PubMed ID: 37646790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgLON5-IgG: Innocent Bystander or Perpetrator?
    Andersen J; Jeffrey B; Varikatt W; Rodriguez M; Lin MW; Brown DA
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgLON5 disease as a differential diagnosis of multiple system atrophy.
    Ono Y; Tadokoro K; Yunoki T; Yamashita T; Sato D; Sato H; Akamatsu S; Mizukami H; Ohta Y; Yamano Y; Kimura A; Shimohata T
    Parkinsonism Relat Disord; 2024 Jul; 124():106992. PubMed ID: 38701719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgLON5 deficiency produces behavioral alterations in a knockout mouse model.
    Landa J; Serafim AB; Alba M; Maudes E; Molina-Porcel L; Garcia-Serra A; Mannara F; Dalmau J; Graus F; Sabater L
    Front Immunol; 2024; 15():1347948. PubMed ID: 38370417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.